Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (291)	5/7/2000 2:46:00 PM
From: gao seng	Read Replies (2) \| Respond to of 746

Good background information, including this little tidbit that I wasn't aware of: Both sides announced milestones along the way. Most notably, the public genome project published a paper in December that said it had for the first time deciphered the genetic code of an entire human chromosome. But, in fact, large areas of chromosome 22 were not sequenced at all. latimes.com Really is an exciting little war. Of course, the consortium doesn't stand a chance against Venter. Cute little sayings like "If people want to view it as a race, it is a race to the starting line" speak volumes to the confidence he has and the implications of the race. With the implications being of course that the loser goes home and won't even be a contender in the 100 year race! Also, article suggests that loss of public funding is at stake for consortium.

To: gao seng who wrote (291)	5/8/2000 2:49:00 AM
From: GlobalMarine	Read Replies (2) \| Respond to of 746

Gao Seng: Thanks for the article. I don't know how you feel about things, but I rather feel Celera should simply do what the other public genomics companies are doing and not bother releasing its database. Instead, Celera should just go full steam ahead identifying therapeutic genes and patenting same. THAT is where the big money is down the road, partnering with a gene delivery co. like TGEN or AVGN to produce gene therapy drugs. I don't think the company is going to make a killing on on subscriptions, esp. after the HGP will provide cheap access to its database. I have to believe Venter is smart enough to realize that the other competing genomics companies are patenting therapeutic genes and not wasting time thinking about subscriptions. Of course, Celera has put itself on the front pages of newspapers and if it decided to keep the database to itself, they'd be some political fallout. But since the HGP is going to release everything anyway, I say damn the torpedoes, full speed ahead. Global